Josh Brown's 'Best Stocks in the Market': Veeva Systems

Core Insights - The focus is on Viva Systems, which has shown significant performance and is becoming a key player in the pharmaceutical and biotech industries [1][2]. Company Performance - Viva's stock broke out in May and has been consolidating just below its 52-week highs [2]. - The company has achieved a net income of $714 million this year, a 36% increase from $525 million in fiscal year 2024 [5]. - Operating margins have improved to 25.2%, marking this year as the most profitable in absolute dollar terms since 2020 [5]. Product Development - Viva has transitioned from using Salesforce to developing its own CRM platform called Vault CRM, which has contributed to its growth [4]. - The company has signed significant deals with major healthcare firms, including Bristol Myers [4][6]. Market Position - Viva is becoming the industry standard CRM platform for drug discovery, indicating strong market demand [3]. - The stock is considered not cheap but is operating at a high level, with a critical resistance level at $300 [6]. Investment Considerations - A stop loss is suggested between $260 to $265, which was prior resistance and is now seen as support [7].